Receive The Newest Study Notifications

First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells...

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for...

Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified Phase 2 IPF trial funded by NIH; poised to initiate patient enrollment following recently received FDA and...

BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

NIH has issued a new definition of what constitutes a clinical trial.  The new definition expands research to be included to virtually any behavioral or biological response to a manipulation or intervention and does not have to include a potential clinical...

December 2, 2019 — Amsterdam, the Netherlands – Royal Philips announced a major clinical trial to assess the impact of a ‘Direct to Angio Suite’ workflow on stroke patient outcomes. The study will assess whether with Philips’ advanced image-guided therapy platform it...

COLUMBIA, S.C., Dec. 2, 2019 /PRNewswire/ -- Healthy Humming, LLC is pleased to announce positive topline data from a prospective outcomes study, which assessed the safety and efficacy of the SinuSonic, a nasal congestion treatment device that combines nasal acoustic...

- Companies to Initiate Phase 3 Trial to Support Global Registrations - BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a...

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE,...

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind,...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dec 2, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia. CTP-692 is a deuterated form of D-serine, an...

BARCELONA, Spain, Dec. 2, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by...

JERSEY CITY, N.J., Dec. 2, 2019 /PRNewswire-PRWeb/ -- TrialScope, the global leader in clinical trial transparency and disclosure compliance solutions, has worked with EMD Serono, the North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany,...

SUZHOU, China, Nov. 26, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and...

LOS ANGELES--(BUSINESS WIRE)--OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful...

Non-muscle-invasive bladder cancer (NMIBC) is the most common neoplasm of the urinary tract and requires life-long invasive surveillance to detect disease recurrence. Currently, there are no effective oral therapies that delay disease recurrence or progression. We...

Eugen will support the expansion of Clinerion’s Patient Network Explorer to hospitals and clinical trial sites in Uruguay. Eugen will also offer Patient Network Explorer services on behalf of Clinerion to clinical researchers and trial sponsors in Uruguay. MONTEVIDEO,...

IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO Topline results from the ASCEND-GO 2 program are expected in early 2021...

Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia While bevacizumabparticularly blocks the signaling activated by VEGF-A, Olinvacimab manages to block the signaling activated by VEGF-A, C, and D. PharmAbcine,...

BOSTON and CARLSBAD, Calif., Nov. 25, 2019 -- Akcea Therapeutics Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.,  and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial...